



Review

Long-term health and psychological complications in recovered COVID-19 patients: A study in Dhaka city

Md. Monir Hossain Shimul^{a,*}, Salamat Khandker^a and Salim Khan^b

^a Department of Public Health, Daffodil International University, Dhaka, Bangladesh

^b Faculty of Health, Education and Life Sciences, Birmingham City University, UK



ARTICLE INFO

Article history:

Received 26 November 2024

Accepted 6 January 2025

Available online 26 February 2025

Keywords:

COVID-19

Post-COVID complications

Long COVID

Bangladesh

Psychological impact

Comorbidities

A B S T R A C T

Background: Recovery from COVID-19 can be accompanied by persistent symptoms and complications, collectively termed post-COVID syndrome or 'long COVID'. This study explores the prevalence and nature of long-term physical and psychological complications among recovered COVID-19 patients in Dhaka, six months post-discharge.

Methods: A cross-sectional study was conducted with 384 patients from COVID-dedicated hospitals in Dhaka. Data on psychological and physical outcomes, including fatigue, insomnia, and dementia, were collected using validated tools. Confidence intervals (CIs) were used to examine associations and determine statistical significance.

Results: Among the participants, the most common symptoms at hospital admission were cough (93.9%), fever (87.2%), and dyspnea (66.9%). Post-discharge, 74% of respondents reported health issues, with general weakness (58.5%) being the most common. Older participants (≥ 50) had a higher likelihood of longer hospital stays, with only 35.9% hospitalized for ≤ 7 days (CI: 45%–55% in < 50). They also exhibited higher comorbidity rates, including hypertension (57.1%; CI: 38%–45%) and diabetes (53.7%; CI: 22%–28%). Older participants were more likely to experience complications, with 93.1% reporting at least one (CI: 65%–75%). Insomnia was prevalent in both age groups (82.0%; CI: 78%–85%), with dementia more common in older participants (34.6%; CI: 25%–35%).

Conclusions: While older adults exhibited higher rates of dementia and longer hospital stays, the high prevalence of psychological complications across all groups emphasizes the need for comprehensive post-COVID care strategies, particularly for older patients.

© 2025 The Author(s). Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).

Complicaciones psicológicas y de salud a largo plazo en pacientes recuperados de COVID-19: un estudio en la ciudad de Dhaka

R E S U M E N

Antecedentes: La recuperación de la COVID-19 puede ir acompañada de síntomas y complicaciones persistentes, denominados colectivamente síndrome post-COVID o "COVID prolongado". Este estudio explora la prevalencia y la naturaleza de las complicaciones físicas y psicológicas a largo plazo entre los pacientes recuperados de COVID-19 en Dhaka, seis meses después del alta.

Métodos: se realizó un estudio transversal con 384 pacientes de hospitales dedicados a la COVID en Dhaka. Los datos sobre resultados psicológicos y físicos, incluida la fatiga, el insomnio y la demencia, se recopilaron mediante herramientas validadas. Se utilizaron intervalos de confianza (IC) para examinar las asociaciones y determinar la significación estadística.

Resultados: Entre los participantes, los síntomas más frecuentes al ingreso hospitalario fueron tos (93,9%), fiebre (87,2%) y disnea (66,9%). Después del alta, el 74% de los encuestados informaron problemas de salud, siendo la debilidad general (58,5%) la más común. Los participantes de mayor edad (≥ 50) tuvieron una mayor probabilidad de estancias hospitalarias más prolongadas, con solo el 35,9% hospitalizados durante ≤ 7 días (IC: 45%–55% en < 50). También mostraron tasas de comorbilidad más altas, incluida hipertensión (57,1%; IC: 38%–45%) y diabetes (53,7%; IC: 22%–28%). Los participantes de mayor edad tenían más probabilidades de

Palabras clave:

COVID-19

Complicaciones post-COVID

COVID prolongado

Bangladesh

Impacto psicológico

Comorbilidades.

* Corresponding author: Department of Public Health, Daffodil International University, Birulia, Savar, Dhaka 1216, Bangladesh.

E-mail address: shimul2375@gmail.com (M.M.H. Shimul).

experimental complicaciones: el 93,1% informó al menos una (IC: 65%–75%). El insomnio fue prevalente en ambos grupos de edad (82,0%; IC: 78%–85%), y la demencia fue más común en los participantes de mayor edad (34,6%; IC: 25%–35%).

Conclusiones: Si bien los adultos mayores mostraron tasas más altas de demencia y estancias hospitalarias más prolongadas, la alta prevalencia de complicaciones psicológicas en todos los grupos enfatiza la necesidad de estrategias integrales de atención post-COVID, particularmente para los pacientes mayores.

© 2025 Los Autores. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC (<http://creativecommons.org/licenses/by-nc/4.0/>).

Introduction

Recovery from COVID-19 infection varies. A majority of those infected will have minimal health problems after recovery; however, some individuals experience long-term symptoms and complications¹, referred as 'post-acute sequelae of SARS-CoV-2 infection (PASC)' or 'long COVID'² when signs and symptoms last longer than 12 weeks³. Eighty-seven percent (87%) of COVID-19 patients had at least one symptom two months after their initial diagnosis⁴. Sudre et al., (2021) reported that those within the age range ≥ 70 years, of female gender, and had the presence of five or more symptoms during the acute phase of COVID-19 infection were associated with an increased risk of developing long COVID⁵ and individuals with pre-existing medical conditions such as hypertension, diabetes, and chronic lung disease, were also at increased risk of developing long COVID⁶. Long COVID, also referred to as post-pandemic syndrome, can have a significant impact on the physical, mental, and social well-being of affected individuals and hence significantly affect their ability to carry out daily activities⁷. Persistent symptoms included fatigue, dyspnea, chest pain, and cognitive impairment^{4,8}.

Understanding the incidence, nature, and severity of post-COVID complications is crucial for healthcare professionals to provide optimal care, and also for public health policymakers to plan effective strategies for managing the long-term health consequences of the pandemic. In light of these considerations, this research on post-COVID complications among recovered patients has significant implications for care, clinical practice, and public health.

Materials and methods

Study design and setting

This cross-sectional study was conducted among COVID-19 patients treated according to the World Health Organization (WHO) criteria in selected COVID-dedicated hospitals in Dhaka city. The study aimed to assess the long-term psychological and physical outcomes in patients who had recovered from COVID-19 infection.

Sample size and participants

The sample size was calculated using the formula: $n = z^2pq/d^2$, where z corresponds to the z -score for a 95% confidence level (1.96), p represents the estimated prevalence of the outcome (50%), and d is the margin of error (5%). To insure a representative estimate of post-COVID complications and reliable findings, data were collected from the resulted sample size of 384 recovered patients who had been discharged from the hospital at least six months prior to the study.

Data collection procedure

Data were collected from individuals who had recovered from COVID-19 at least six months prior to the study. Patients were initially contacted by phone, and the nature of the study was explained.

After obtaining verbal consent, they were invited to a designated outpatient department. Written consent was subsequently obtained before administering a pre-tested, Bangla-translated version of the Depression, Anxiety, and Stress Scale (DASS-21) through face-to-face interviews.

Quality control

The data collection team received rigorous training on administering the assessment tools to insure consistency and minimize bias. The Bangla-translated versions of the scales were pre-tested on a small group of participants to confirm clarity and cultural appropriateness. Data were cross-checked for completeness and accuracy before analysis.

Inclusion and exclusion criteria

The study included patients who met specific inclusion criteria to insure the relevance and reliability of the findings. Participants had to be 18 years of age or older and have recovered from COVID-19 at least six months prior to data collection. Additionally, only those who were willing to provide informed consent were eligible to participate in the study. Patients were excluded if they had pre-existing severe psychiatric or neurological conditions, as these could confound the assessment of post-COVID-19 outcomes. Individuals who were unwilling to participate or unable to provide informed consent were also excluded from the study. These criteria were designed to insure a homogeneous study population and enhance the validity of the results.

Assessment tools

The **Depression, Anxiety, and Stress Scale (DASS-21)** was used to evaluate emotional well-being. This scale comprises 21 items divided into three subscales, each with seven items focusing on depression, anxiety, and stress. The depression subscale assessed feelings of dysphoria, hopelessness, lack of interest, and anhedonia, while the anxiety subscale evaluated autonomic arousal, situational anxiety, and anxious affect. The stress subscale measured difficulty relaxing, nervous arousal, irritability, and over-reactivity. Participants responded to each item on a 4-point Likert scale, and their scores were categorized as indicating depression (above 9), anxiety (above 7), or stress (above 14)⁹. Insomnia was assessed using a dedicated 7-item scale, with each item scored from 0 to 4; a total score above 7 was indicative of insomnia¹⁰.

To measure physical and cognitive health, the study employed the **Fatigue Assessment Scale (FAS)** and the **Self-Administered Gerocognitive Exam (SAGE)**. The FAS consisted of 10 items scored on a 5-point scale, with scores above 18 indicating varying levels of fatigue¹¹. The SAGE test, designed to evaluate cognitive functions, included 12 items covering memory, judgment, problem-solving, language, and visual-spatial abilities. Together, these tools provided a comprehensive understanding of the participants' mental, emotional, and cognitive health status, facilitating a multidimensional analysis of post-COVID-19 outcomes.

Table 1
Socio demographic characteristics and clinical manifestations of respondents.

Demographic Characteristics		Frequency	Percentage
Age in years	Up to 25	48	12.5
	26–45	160	41.8
	46–65	148	38.4
	>65	28	7.2
Religion	Islam	315	82.1
	Hindu	69	17.9
Education	Up to Primary	28	7.2
	Secondary	86	22.4
	Higher Grade	186	48.5
Occupation	Above Grade	84	21.9
	Government Service	23	6.1
	Private Service	112	29.1
	Business	60	15.5
	Housewife	113	29.3
	Labour	72	18.7
	Others	04	1.3
Family Income	Upto 15,000	68	17.5
	15,001–25,000	99	25.8
	25,001–35,000	116	30.3
	>35000	101	26.4
Common clinical manifestations	Cough	360	93.9
	Fever	335	87.2
	Dyspnea	257	66.9

Data analysis

Collected data were analyzed using the latest version of SPSS for Windows. Descriptive statistics were used to summarize the data, while inferential statistics were applied to explore associations between variables with confidence intervals (CIs) used to assess statistical significance.

Results

The majority of respondents were either employed in the private sector or were housewives (Table 1). Most participants were aged between 26–45 years (41.8%) and 46–65 years (38.4%). Nearly half had completed higher education, while more than one-third reported a monthly income of 25,001–35,000 BDT, which is considered below average¹². The most common clinical symptoms at the time of hospital admission were cough (93.9%), fever (87.2%), and dyspnea (66.9%). Other symptoms, though less frequently reported, included chest pain, joint pain, loss of appetite, myalgia, diarrhea, headache, anosmia, vertigo, red eyes, and sore throat.

Approximately, 74% of respondents reported health problems after hospital discharge (Table 2). The most commonly reported symptoms were general weakness (58.5%), joint pain (24.1%), headache (18.4%),

Table 2
Distribution of respondents by Health Problems after release from Hospital (n = 384).

Health Problems after release from Hospital	Yes (%)	No (%)
Have health problem	283 (73.7)	101 (26.3)
General Weakness	224 (58.5)	160 (41.5)
Chronic Cough	60 (15.7)	324 (84.3)
Difficulty in respiration	25 (6.7)	359 (93.3)
Anorexia	56 (14.7)	328 (85.3)
Vertigo	56 (14.7)	328 (85.3)
Joint pain	92 (24.1)	292 (75.9)
Headache	70 (18.4)	314 (81.6)
Bodyache	56 (14.7)	328 (85.3)
Chest pain	21 (5.7)	363 (94.3)
Muscle pain/spasm	20 (5.4)	364 (94.6)
Fatigue	16 (4.3)	368 (95.7)
Insomnia	57 (15.0)	327 (85.0)
Hair Loss	10 (2.7)	374 (97.3)
Other problems	26 (7.0)	358 (93.0)
Follow doctor's advice	304 (79.2)	80 (20.8)

Table 3
Relationship Between Age and Length of Hospital Stay (n = 384).

Hospital Stay (Days)	Age < 50 Frequency (%)	Age ≥ 50 Frequency (%)	Total Frequency (%)	95% CI
≤7	119 (50.2%)	53 (35.9%)	172 (44.8%)	0.45–0.55
8–14	91 (38.4%)	63 (42.9%)	154 (40.1%)	0.35–0.50
15–21	23 (9.7%)	28 (19.2%)	51 (13.3%)	0.10–0.15
>21	4 (1.9%)	3 (1.9%)	7 (1.8%)	0.01–0.05
Total	237 (61.7%)	147 (38.2%)	384 (100%)	–
Mean ± SD	9.1 ± 4.739	10.3 ± 4.564	9.6 ± 4.704	–

and chronic cough (15.7%). At least 80% of respondents indicated adherence to their doctors' advice post-discharge.

Participants aged ≥50 had a higher likelihood of longer hospital stays compared to those aged <50. The Confidence Intervals (CIs) indicate that 45% to 55% of participants aged <50 were hospitalized for ≤7 days, while for participants aged ≥50, this proportion was only 35.9%. This trend persists for the 15–21 day range, where older participants were disproportionately represented (19.2%; CI: 10%–15%) (Table 3).

Older participants (≥50) exhibited a higher prevalence of comorbidities, such as hypertension (57.1%; CI: 38%–45%), diabetes mellitus (53.7%; CI: 22%–28%), and cardiovascular disease (14.2%; CI: 8%–10%). The younger group (<50) showed fewer comorbidities overall, with dyslipidemia (1.2%; CI: 3%–5%) and kidney disease (1.7%; CI: 1%–3%) being the least common (Table 4).

In Table 5, complications were more common among participants aged ≥50, with 93.1% reporting at least one complication (CI: 65%–75%), compared to 70% in the <50 age group. Specific complications, such as sleeplessness (8.8%; CI: 2%–7%), vertigo (19.7%; CI: 10%–16%), and chronic cough (21.7%; CI: 12%–18%), were disproportionately higher in older participants.

The results from Table 6 focus on psychological complications such as suffering, anxiety, and insomnia were prevalent across both age groups, with insomnia being the most common issue (82.0%; CI: 78%–85%). Notably, dementia was more prevalent among older participants (34.6%; CI: 25%–35%) compared to younger participants (24.1%; CI: 20%–30%), reflecting the potential neurological impact of COVID-19 on older individuals. Although the prevalence of PTSS (14.3%; CI: 10%–18%) and depression (10.9%; CI: 8%–15%) was slightly higher in older participants, these differences were not as pronounced. These results highlight the need for mental health support as a critical component of post-COVID care, particularly for older adults.

Discussion

This study focused on individuals who were hospitalized due to COVID-19 and released at least six months prior to the commencement of the study. Statistically noteworthy differences were observed for the proportion of respondents, particularly within the 26–35 years age range, who reported ongoing health issues post-recovery, aligning

Table 4
Distribution by Age and Co-Morbidity (n = 384).

Co-Morbidities	Age < 50 Frequency (%)	Age ≥ 50 Frequency (%)	Total Frequency (%)	95% CI
Suffering	115 (48.5%)	140 (95.2%)	255 (66.4%)	0.60–0.70
No Suffering	122 (51.5%)	7 (4.8%)	129 (33.6%)	0.30–0.40
Hypertension	75 (31.6%)	84 (57.1%)	159 (41.4%)	0.38–0.45
Diabetes Mellitus	22 (9.2%)	79 (53.7%)	101 (26.3%)	0.22–0.28
Cardiovascular Disease	14 (5.9%)	21 (14.2%)	35 (9.1%)	0.08–0.10
Asthma	35 (14.7%)	7 (4.7%)	42 (16.5%)	0.14–0.18
Dyslipidemia	3 (1.2%)	12 (8.1%)	15 (3.9%)	0.03–0.05
Hypothyroidism	4 (1.7%)	9 (6.1%)	13 (3.4%)	0.02–0.04
Kidney Disease	4 (1.7%)	4 (2.0%)	8 (2.1%)	0.01–0.03

Table 5
Age and COVID-19 Complications After Treatment (n = 384).

Complications	Age < 50 Frequency (%)	Age ≥ 50 Frequency (%)	Total Frequency (%)	95% CI
Any Complication	166 (70.0%)	137 (93.1%)	303 (78.9%)	0.65–0.75
No Complication	71 (29.9%)	10 (6.8%)	81 (21.1%)	0.18–0.24
Sleeplessness	6 (2.5%)	13 (8.8%)	19 (4.9%)	0.02–0.07
Vertigo	23 (9.7%)	29 (19.7%)	52 (13.5%)	0.10–0.16
Chronic Cough	25 (10.5%)	32 (21.7%)	57 (14.8%)	0.12–0.18
Weakness	128 (54.0%)	93 (63.2%)	221 (57.5%)	0.50–0.60

with previous studies that suggest COVID-19 survivors may experience lingering effects¹³. According to the WHO's 2023 report, 10–20% of individuals experience a range of mid- and long-term symptoms following COVID-19 recovery¹⁴. In this study, however, the percentage of respondents suffering from post-COVID complications was much higher, with 79% reporting persistent symptoms, a finding far greater than what was reported by the WHO. This disparity may be attributed to the fact that the study sample largely consisted of individuals who had been hospitalized for severe cases of COVID-19, many of whom had pre-existing co-morbidities. The prevalence of co-morbidities in this study was reported at 66%, which is concerning as co-morbid conditions can contribute to prolonged recovery and worsen health outcomes. Previous studies, such as those by Paul et al.¹⁵ and Khandker et al.¹⁶, have reported a lower prevalence of co-morbidities, which further supports the notion that the severity of COVID-19 illness and the presence of underlying conditions influence recovery trajectories.

The length of hospital stay for patients with COVID-19 has been a critical factor in recovery. In this study, patients aged ≥50 experienced longer hospital stays compared to those under 50, aligning with findings by Yusef et al.¹⁷, who also reported extended hospital stays in patients older than 60. Age and underlying comorbidities, including diabetes, chronic kidney diseases, and chronic obstructive pulmonary disease, were associated with prolonged hospital stays and increased illness severity¹⁸. Similarly, a systematic review by Justino et al.¹⁹ found hypertension, diabetes, and respiratory diseases to be the most common comorbidities among COVID-19 patients, particularly in older age groups. These findings highlight the influence of age and co-morbidities on the progression and severity of COVID-19.

Regarding clinical improvements, the study found that individuals under 50 years old demonstrated better recovery outcomes compared to their older counterparts. This observation is consistent with broader research indicating that older adults and individuals with comorbid conditions face a higher risk of severe COVID-19 outcomes, including prolonged symptoms and complications²⁰. Additionally, a systematic review and meta-analysis underscored that individuals aged 50 years or older have an elevated risk of mortality compared to those younger than 50²¹. Co-morbidities such as kidney diseases, cardiovascular disease, and respiratory conditions further compound the risk of severe outcomes, highlighting the importance of managing these conditions in older patients to improve their prognosis.

The study also examined the psychological effects of COVID-19, revealing that a notable proportion of respondents experienced mental

health challenges, including post-traumatic stress syndrome (14.3%), depression (10.9%), and anxiety (34.3%). However, this study did not find a clear relationship between these psychological issues and age, which differs from findings by Hoang et al.^{22,23} in Vietnam, who reported that age was a risk factor for PTSD, anxiety, and depression. The high prevalence of psychological problems observed in this study aligns with other research suggesting that the COVID-19 pandemic has exacerbated mental health issues such as anxiety, depression, and PTSD²⁴. Furthermore, studies conducted in Bangladesh have also documented an increase in psychological problems due to the pandemic, which may contribute to the long-term mental health burden in individuals recovering from COVID-19²⁵.

This study found that dementia was more prevalent in individuals aged ≥50, with the older group exhibiting a notably higher rate of dementia compared to younger individuals. This finding aligns with existing literature indicating that aging increases the risk of developing dementia, a condition potentially exacerbated by the neurological effects of COVID-19²⁶. Several studies have documented that COVID-19 can cause neurological complications such as delirium, stroke, and encephalitis, which may contribute to the development of dementia in the long term²⁷. These results underscore the importance of prioritizing the mental health and neurological well-being of COVID-19 survivors, particularly among older individuals.

Conclusion

The study revealed that a considerable proportion of recovered COVID-19 patients experienced post-COVID complications, with fatigue, shortness of breath, and joint pain being the most common. The majority of respondents had pre-existing comorbidities, and patients aged ≥50 years had a longer average hospital stay compared to those under 50 years. These findings underscore the need to understand the prevalence and nature of post-COVID complications among recovered patients to enhance care and develop effective strategies for managing the long-term health impacts of the pandemic. However, the study's relatively small sample size from a single city limits its generalizability to broader populations of post-COVID patients worldwide.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical consideration

Ethical approval for the study was obtained from the Research Ethics Committee of the Faculty of Health and Life Sciences, Daffodil International University, Dhaka, Bangladesh. The approval reference number was [FAHSREC/DIU/2023/SMIG-61]. In addition, permission to conduct the study was granted by the hospital authorities. Before beginning the data collection, participants were informed about the objectives, methods, and potential benefits of the study through an information sheet provided in Bengali. They were assured that their participation was voluntary and that they could withdraw at any time without any consequences. Informed verbal consent was obtained from each participant before the interview. The study adhered to the ethical principles outlined in the Declaration of Helsinki and insured that no harm came to participants as a result of their involvement.

CRediT authorship contribution statement

Md. Monir Hossain Shimul: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing. **Salamat Khandker:** Supervision, Writing – review & editing. **Salim Khan:** Methodology, Writing – review & editing.

Table 6
Age and Psychological Problems After Release from Hospital (n = 384).

Psychological Problems	Age < 50 Frequency (%)	Age ≥ 50 Frequency (%)	Total Frequency (%)	95% CI
Suffering	187 (78.9%)	131 (89.1%)	318 (82.8%)	0.75–0.85
PTSS	29 (12.2%)	26 (17.7%)	55 (14.3%)	0.10–0.18
Depression	31 (13.1%)	11 (7.4%)	42 (10.9%)	0.08–0.15
Anxiety	79 (33.3%)	53 (36.1%)	132 (34.3%)	0.30–0.40
Chronic Fatigue	47 (19.9%)	21 (14.2%)	68 (17.7%)	0.15–0.20
Insomnia	193 (81.4%)	122 (82.9%)	315 (82.0%)	0.78–0.85
Dementia	57 (24.1%)	51 (34.6%)	108 (28.1%)	0.25–0.35

Conflict of interest

The authors declare that there are no conflicts of interest regarding the publication of this paper. All the authors reviewed and approved the final manuscript. No financial relationships relevant to this article were disclosed by any of the authors.

Acknowledgements

The authors are grateful to all the dear patients and respective hospital authorities who participated in this project.

Appendix A. STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1–2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1–2
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State-specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5–6
Bias	9	Describe any efforts to address potential sources of bias	5–6
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	5–6
		(d) If applicable, describe analytical methods taking account of sampling strategy	5
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	6
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6–7
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	6–7
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6–7
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarize key results with reference to study objectives	7–8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both the direction and magnitude of any potential bias	8
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	7–8
Generalisability	21	Discuss the generalizability (external validity) of the study results	7–8
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

* Give information separately for exposed and unexposed groups.

Data availability

The data supporting the conclusions of this article are included within the article.

References

- Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its management. *Int J Biol Sci*. 2022;18(12):4768–80.
- Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27(4):601–15 Available from: <https://doi.org/10.1038/s41591-021-01283-z>.
- Debski M, Tsampasian V, Haney S, Blakely K, Weston S, Ntatsaki E, et al. Post-COVID-19 syndrome risk factors and further use of health services in East England. *PLOS Glob Public Heal*. 2022;2(11), e0001188 Available from: <https://doi.org/10.1371/journal.pgph.0001188>.
- Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *JAMA - J Am Med Assoc*. 2020;324(6):603–5.
- Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nat Med*. 2021;27(4):626–31.
- Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry*. 2021;8(5):416–27 Available from: [https://doi.org/10.1016/S2215-0366\(21\)00084-5](https://doi.org/10.1016/S2215-0366(21)00084-5).
- Mahase E. Covid-19: what do we know about 'long covid'? *BMJ*. 2020;370:9–10.
- Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220–32 Available from: [https://doi.org/10.1016/S0140-6736\(20\)32656-8](https://doi.org/10.1016/S0140-6736(20)32656-8).
- Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. *Sleep*. 2011;34(5):601–8 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079939/>.
- Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales 2nd ed. ; 1995. Sydney Psychology Foundation of Australia. - References - Scientific Research Publishing [Internet]. Scirp.org. 2014 [cited 2019 Nov 27]. Available from: [https://www.scirp.org/\(S\(vtj3fa45qm1ean45vffcz55\)\)/reference/ReferencesPapers.aspx?ReferenceID=1262988](https://www.scirp.org/(S(vtj3fa45qm1ean45vffcz55))/reference/ReferencesPapers.aspx?ReferenceID=1262988).
- Examination of the Dimensionality of Fatigue: The Construction of the Fatigue Assessment Scale (FAS). [Internet]. ResearchGate. Available from: https://www.researchgate.net/publication/228079541_Examination_of_the_Dimensionality_of_Fatigue_The_Construction_of_the_Fatigue_Assessment_Scale_FAS.
- Bangladesh Bureau of Statistics (BBS). Household Income and Expenditure Survey (HIES) 2022: Key Findings; 2023;1–48.
- Kawaura F, Kishi T, Yamamoto T, Nakayama S, Goto T, Tsurusawa R, et al. Age distribution and disease severity of COVID-19 patients continued to change in a time-dependent manner from May 2021 to April 2022 in the regional core hospital in Japan. *Drug Discov Ther*. 2023;17(1):60–5.
- WHO. Coronavirus Disease (COVID-19): Post COVID-19 Condition. [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-post-covid-19-condition](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition) (Access 2.08.2023).
- Paul A, Sharif MM, Bari MS, Miah MT, Amin MR, Mahanta J, et al. Comorbidity and Post-COVID-19 complications of hospitalized patients in Bangladesh. *Asia-Pacific J Public Heal*. 2023;35(4):318–9.
- Khandker S, Akther A, Syed BH, Shafiullah R, Ahmed K, Chowdhury AA, et al. Post-COVID-19 complications in home and hospital-based care: a study from Dhaka city. *Bangladesh Front Rehabil Sci*. 2022;3(November):1–11.
- Alimohamadi Y, Yekta EM, Sepandi M, Sharafoddin M, Arshadi M, Hesari E. Hospital length of stay for COVID-19 patients: a systematic review and meta-analysis. *Multidiscip Respir Med*. 2022;17.
- Henkens MTHM, Raafs AG, Verdonchot JAJ, Linschoten M, van Smeden M, Wang P, et al. Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study. *BMC Geriatr*. 2022;22(1):1–11.
- Justino DCP, Silva DFO, Costa KTDS, De Moraes TNB, De Andrade FB. Prevalence of comorbidities in deceased patients with COVID-19: a systematic review. *Med (United States)*. 2022;101(38), E30246.
- Yang J, Zheng Y, Gou X, Pu K, Chen Z. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis*. 2020;94(March):91–5 Available from: <https://doi.org/10.1016/j.arteri.2020.10.001>.
- Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. *Intervirology*. 2021;64(1):36–47.
- Afshin A, Sur PJ, Fay KA, Cornaby L, Ferrara G, Salama JS, et al. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2019;393(10184):1958–72.
- Nguyen HB, Nguyen THM, Vo THN, Vo TCN, Nguyen DNQ, Nguyen HT, et al. Post-traumatic stress disorder, anxiety, depression and related factors among COVID-19 patients during the fourth wave of the pandemic in Vietnam. *Int Health*. 2023;15(4):365–75.
- Kandeger A, Guler HA, Egilmez U, Guler O. Major depressive disorder comorbid severe hydrocephalus caused by Arnold – Chiari malformation Does exposure to a seclusion and restraint event during clerkship influence medical student ' s attitudes toward psychiatry? *Indian J Psychiatry*. 2018;59(4):2017–8.
- Livingston G, Sommerlad A, Orgeta V, Costafrida SG, Huntley J, Ames D, et al. The Lancet Commissions Dementia prevention, intervention, and care. *Lancet*. 2017;390(17):2673–734 Available from: [https://doi.org/10.1016/S0140-6736\(20\)30367-6](https://doi.org/10.1016/S0140-6736(20)30367-6).
- Alzheimer's Association. 2021 Alzheimer's Disease Facts and Figures. *Alzheimer's & Dementia* [Internet]. 17(3); 2021 Mar 23. Available from: <https://pubmed.ncbi.nlm.nih.gov/33756057/>.
- Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry*. 2020;7(10):875–82.